Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $28.6667.

KYTX has been the subject of several research analyst reports. Morgan Stanley set a $33.00 price target on Kyverna Therapeutics in a report on Monday, December 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Monday, December 29th. Wall Street Zen cut shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 14th. HC Wainwright upped their price target on shares of Kyverna Therapeutics from $10.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, October 27th. Finally, Wells Fargo & Company lifted their price objective on shares of Kyverna Therapeutics from $31.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th.

Kyverna Therapeutics Price Performance

Shares of KYTX opened at $8.10 on Friday. The firm has a market cap of $354.78 million, a P/E ratio of -2.17 and a beta of 3.45. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $13.67. The company has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $6.72.

Insider Buying and Selling

In related news, Director Beth C. Seidenberg acquired 133,333 shares of the firm’s stock in a transaction on Thursday, December 18th. The shares were acquired at an average cost of $7.50 per share, for a total transaction of $999,997.50. Following the completion of the transaction, the director directly owned 869,317 shares in the company, valued at approximately $6,519,877.50. This trade represents a 18.12% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Biopartners Opportuni Westlake acquired 133,333 shares of the stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $7.50 per share, with a total value of $999,997.50. Following the completion of the purchase, the insider directly owned 869,317 shares in the company, valued at approximately $6,519,877.50. The trade was a 18.12% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 22.00% of the stock is currently owned by company insiders.

Institutional Trading of Kyverna Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Kyverna Therapeutics in the third quarter worth approximately $28,000. Phoenix Wealth Advisors bought a new position in Kyverna Therapeutics in the 2nd quarter valued at $32,000. Catalyst Funds Management Pty Ltd purchased a new stake in Kyverna Therapeutics in the second quarter worth $37,000. Qube Research & Technologies Ltd bought a new stake in shares of Kyverna Therapeutics during the second quarter worth $43,000. Finally, Ethic Inc. purchased a new stake in shares of Kyverna Therapeutics during the second quarter valued at $56,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.